



# The European Union comes to BIO International Convention!

Join us at the EU pavilion:  
your one-stop shop for information  
on research and innovation funding,  
regulatory issues, and partnering  
opportunities in the European Union



@EUScienceInnov  
@IMI\_JU  
@EMA\_News  
#EUHealthResearch  
#BIO2018



# European Commission, Directorate-General for Research & Innovation



The European Union is present at BIO US through the Directorate-General for Research and Innovation of the European Commission, which is in charge of defining and implementing European research and innovation policies. These policies are supported by Horizon 2020, the largest and most ambitious program for research and innovation undertaken by the European Union ever – worth €80 billion – and among the largest in the world.

Horizon 2020 is open for business and offers considerable support for researchers operating in the life science and healthcare research cycle, including for the digital and personalised transformation of health and care. User friendly for companies looking for high growth – with disruptive ideas – offering them funding and business support, Horizon 2020 provides tailor-made instruments for the varying needs of health research companies and SMEs.

In recognition of the opening of the US National Institutes of Health's programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding to support its participation in most of the projects supported under Horizon 2020 Societal Challenge "Health, Demographic Change and Wellbeing".

## JOIN OUR MINI-SESSIONS AT THE EU PAVILION - BOOTH 1943

European research funding opportunities – what's in it for you?

June 5, 11:00 AM – 11:30 AM  
June 5, 2:30 PM – 3:00 PM

Pitch Session of EU start-ups – Enterprise Europe Network

June 5, 4:45 PM – 5:30 PM  
June 6, 4:30 PM – 5:30 PM

What is Horizon Europe – the brand new EU programme for research and innovation

June 6, 11:00 AM – 11:30 AM  
June 7, 11:00 AM – 11:30 AM

How to find your way to EU funding programs? How to collaborate with NIH and DoD with the support of the Enterprise Europe Network?

June 6, 2:00 PM – 3:00 PM



<http://ec.europa.eu/research/health/>  
<http://ec.europa.eu/programmes/horizon2020/>



@EUScienceInnov  
#EUHealthResearch  
#BIO2018



# Innovative Medicines Initiative (IMI)



The Innovative Medicines Initiative (IMI) is globally recognized as a pioneer of open innovation and an attractive model for successful public-private partnerships (PPPs) in research.

A partnership between the European Union (EU) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), our goal is to improve health by speeding up the development of innovative medicines, particularly in areas where there is an unmet medical or social need.



efpia

We do this by supporting collaborative projects that bring together all key groups involved in life science research. Through our projects, we are finding innovative solutions to the most pressing medical burdens of our time, including antimicrobial resistance, dementia, and diabetes.

Eligible universities, small companies, biotechs, patient groups and regulatory bodies receive funding to support their participation in our projects.

We also offer large companies and organizations the opportunity to invest in our projects and become IMI Associated Partners. Associated Partners enjoy benefits such as access to complementary skills, expertise, technology and data; the opportunity to share knowledge and risks in a non-competitive space; and the more efficient use of resources.

## FIND US IN THE BIO EDUCATION PROGRAM

Will public-private partnerships take the leap into open science?

Tuesday, June 5, 11:00 – 12:00

Room 252AB, Level 2

Session ID 19842

The Value of Vaccines in AMR

Wednesday, June 6, 1:45 – 2:45

Room 251, Level 2

Session ID 36185



[www.imi.europa.eu](http://www.imi.europa.eu)



@IMI\_JU



# European Medicines Agency (EMA)



EUROPEAN MEDICINES AGENCY  
SCIENCE · MEDICINES · HEALTH

The European Medicines Agency (EMA) is responsible for the scientific evaluation, supervision and safety monitoring of medicines for human and veterinary use in the European Union (EU).

As an enabler of innovation, EMA encourages research and development of new medicines, including those for patients with rare diseases and for children. Special programs, such as the PRIME (PRiority Medicines) scheme, facilitate early enhanced interaction with developers of promising medicines that may address patients' unmet needs.

To support innovation and development by micro, small and medium-sized enterprises, EMA has a dedicated SME office that provides tailored assistance on regulatory, financial and administrative matters.

EMA and the US FDA cooperate on more than 20 platforms (most involving also other regulators) on different therapeutic areas, patient populations and types of activities, including inspections. Scientific advice requests can be submitted by sponsors in parallel to EMA and FDA at any stage of the development of medicines. The goal is to ensure convergence in requirements for global clinical studies and global development.

Scientific guidance and scientific advice from EMA help medicines developers translate progress in medical science into medicines that bring real public health benefits for all citizens.

## JOIN OUR MINI-SESSION AT THE EU PAVILION - BOOTH 1943


European Medicines Agency: International cooperation and SME support  
June 5, 4:00 PM – 4:45 PM



[www.ema.europa.eu/ema/](http://www.ema.europa.eu/ema/)



@EMA\_News



# Contact us at BIO:

## European Commission, Directorate-General for Research & Innovation



**Cornelius Schmaltz,**  
Head of Unit,  
Health Strategy,  
cornelius.schmaltz@ec.europa.eu



**Maria Pilar Aguar-Fernandez,**  
Head of Unit, Innovative tools,  
technologies and concepts  
in health research,  
pilar.aguar@ec.europa.eu



**Elmar Nimmessgern**  
Deputy Head of Unit,  
Innovative and Personalised Medicine  
elmar.nimmessgern@ec.europa.eu



**Hilde Somers**  
Financial officer,  
Health Strategy  
hilde.somers@ec.europa.eu



**Dan Nacu-Manole**  
Information and Communication Officer,  
Health Strategy  
dan.nacu-manole@ec.europa.eu

## Innovative Medicines Initiative (IMI)



**Pierre Meulien**  
Executive Director  
pierre.meulien@imi.europa.eu



**Magali Pointot**  
Advisor to the Executive Director  
magali.pointot@imi.europa.eu



**Catherine Brett**  
External Relations Manager  
catherine.brett@imi.europa.eu

## European Medicines Agency (EMA)



**Tania Teixeira,**  
European Medicines Agency  
Liaison Officer at the FDA,  
tania.teixeira@ema.europa.eu



**Leonor Enes,**  
Scientific Officer in the European Medicines  
Agency SME office,  
Leonor.Enes@ema.europa.eu



MEET US AT THE EU PAVILION  
-BOOTH 1943-